In the context of the COVID-19 crisis, the European Union adopted a regulation providing for a temporary derogation from European legislation on genetically modified organisms. In the context of the SARS-CoV-2 pandemic (COVID-19), the European Union (EU) has adopted the Regulation (EU) 2020/1043 of
On 1 April 2020, the FAMHP took steps regarding a range of medicinal products in order to avoid any shortage. Following new information from scientific research, the FAMHP has added dexamethasone-based medicines and raw materials to the list of medicinal products subject to emergency measures.
On 1 April 2020, the FAMHP took steps regarding a range of medicinal products in order to avoid any shortage. These measures have now been extended by one month.
Since the start of the coronavirus pandemic, the FAMHP teams have been working relentlessly and have devoted a lot of resources to monitoring medical devices delivered to Belgium and imported medicinal products.
Since the start of the coronavirus pandemic, the FAMHP teams have been working relentlessly and have devoted a lot of resources to support healthcare professionals and to ensure the quality and safety of medicinal products and medical devices used to treat COVID-19 patients. But the efforts do not stop. The FAMHP is now doing everything to prevent any shortage of medicinal products or medical devices in the event of a second wave of COVID-19.
Since the start of the coronavirus pandemic, the FAMHP teams have been working relentlessly to support hospitals facing difficulties with supplies of medicinal products used in the treatment of COVID-19 patients. In addition, given the specific context of use of these medicinal products, the FAMHP has ensured close monitoring of adverse reactions.
Dosing devices for liquid medicines are generally not interchangeable. To avoid dosing errors, the FAMHP recalls the importance of using the dosing device supplied with the medicine.
Early October 2019, the European Medicines Agency (EMA), together with the European medicines authorities, including the FAMHP, asked all marketing authorisation holders to perform a risk assessment on the presence of nitrosamines as a precaution. The result of this risk assessments (step 1) must be reported via the particular web form before 1 October 2020. Another particular web form is available for submitting the results of the confirmatory tests (step 2).
The new BelVet-SAC report which contains an overview of the use of antibiotics in veterinary medicine is available. The 2019 results confirm the trends of previous years with consumption down 7.8% for mg of active substance/kg of biomass compared to last year. Compared to the 2011 reference year, the use of antibiotics in veterinary medicine has decreased by 40.3%.
On Monday 22 June 2020 AMCRA, FASFC, FAMHP and FPS Public Health will host a webinar presenting the latest results on the use of antibiotics in animals and the fight against antimicrobial resistance.
